Related Experiment Videos
[Left atrial thrombus in multiple myeloma treated with thalidomide]
1Service de cardiologie, hôpital d'instruction des armées Sainte-Anne, 2, bd Sainte-Anne, 83800 Toulon-Naval. christophejego@aol.com
Archives Des Maladies Du Coeur Et Des Vaisseaux
|December 5, 2003
Summary
A rare left atrial thrombus occurred in a myeloma patient without typical causes. Thalidomide
Area of Science:
- Cardiology
- Hematology
- Oncology
Background:
- Left atrial thrombus formation typically requires predisposing hemodynamic factors such as arrhythmias, mitral valve disease, or severe left ventricular dysfunction.
- The occurrence of left atrial thrombus in the absence of these factors is considered a rare clinical event.
Observation:
- This case report details a patient with refractory myeloma who developed a left atrial thrombus.
- The thrombus appeared four months after discontinuing thalidomide treatment.
- Standard hemodynamic risk factors for left atrial thrombosis were ruled out in this patient, who was in sinus rhythm.
Findings:
- The patient presented with a left atrial thrombus despite the absence of common etiological factors.
- The potential contribution of thalidomide to thrombus formation is considered, given recent literature linking this drug to both venous and arterial thrombotic events.
Implications:
- This case highlights a potential, albeit debatable, association between thalidomide and left atrial thrombosis in myeloma patients.
- Further research may be warranted to elucidate the thrombotic risks associated with thalidomide, particularly in complex hematological malignancies.